Alveolar Macrophage Programming Following Endotoxin Exposure
ConditionARDS, Human
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-50
SponsorNational Jewish Health
About this trial
The histologic hallmarks of lung inflammation include accumulation of inflammatory cells in the airspaces and interstitium, injury to alveolar epithelial and endothelial cells, loss of epithelial-capillary integrity and accumulation of edema fluid in the interstitium and airspaces. Accordingly, for alveolar repair to occur inflammation must be halted, debris and inflammatory cells removed, injured tissue cells replaced, and capillary barrier function re-established. Macrophages are key players in all of these. Here the investigators hypothesize that resident alveolar macrophages and recruited macrophages serve completely different functions, acting independently (i.e. division of labor) yet cooperatively (synergism).
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Written, informed consent
Age 18-50
Disqualifiers
Current or recent illness (past 2 weeks)
Presence or prior history of cardiac, pulmonary or systemic disease
Bleeding disorder, use of systemic anticoagulants or antiplatelet therapy
American Society of Anesthesiology (ASA) class 2 or greater
Trial design
Design model
Single group
Treatments tested in this trial
bronchoscopy with intrabronchial administration of lipopolysaccharide
Other interventionThe PI will administer intrabronchial LPS into the lungs of healthy volunteers and then obtaining macrophages by bronchoalveolar lavage (BAL) 24, 48, 72, 96, or 120 hours later.
Treatment groups
25 Participants
are divided into 1 treatment groupGroup A: LPS armExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Resident alveolar macrophages and recruited macrophages will be distinguished from one another using multi-parameter flow cytometry, and the relative proportions enumerated
Resident and recruited macrophages will be purified using fluorescence activated cell sorting (FACS) and subjected to RNA sequencing.
Time frame
7 daysSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov